Connor Clark & Lunn Investment Management Ltd. Sells 17,118 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Connor Clark & Lunn Investment Management Ltd. reduced its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 5.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 306,946 shares of the company’s stock after selling 17,118 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.43% of Kiniksa Pharmaceuticals worth $6,071,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of KNSA. Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals in the third quarter worth about $50,000. China Universal Asset Management Co. Ltd. grew its holdings in Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock valued at $174,000 after buying an additional 1,004 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $189,000. Y Intercept Hong Kong Ltd bought a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter valued at approximately $258,000. Finally, GSA Capital Partners LLP bought a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at approximately $268,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Up 2.0 %

KNSA stock opened at $22.61 on Friday. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $16.56 and a twelve month high of $28.15. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -161.49 and a beta of 0.48. The firm’s fifty day simple moving average is $19.99 and its two-hundred day simple moving average is $22.16.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The firm had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.35 earnings per share. As a group, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Buying and Selling

In related news, CAO Michael R. Megna sold 9,051 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the transaction, the chief accounting officer now owns 26,528 shares of the company’s stock, valued at $595,553.60. This trade represents a 25.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the sale, the chief operating officer now directly owns 81,975 shares of the company’s stock, valued at approximately $1,604,250.75. This trade represents a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 73,423 shares of company stock valued at $1,541,812. Insiders own 54.57% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on KNSA. Wedbush reaffirmed an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $40.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average target price of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.